SEC Filing | EyePoint Pharmaceuticals

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Duker Jay S.

(Last)

(First)

(Middle)

C/O EYEPOINT PHARMACEUTICALS, INC.

480 PLEASANT STREET

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/01/2021

3. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [ EYPT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,657	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	09/26/2026	Common Stock	4,000	31.7	D
Employee Stock Option (right to buy)	⁽²⁾	02/21/2029	Common Stock	4,000	26.5	D
Employee Stock Option (right to buy)	⁽³⁾	06/21/2028	Common Stock	2,666	19.5	D
Employee Stock Option (right to buy)	⁽⁴⁾	02/09/2031	Common Stock	60,300	13.13	D
Employee Stock Option (right to buy)	⁽⁵⁾	02/28/2030	Common Stock	3,350	12.9	D
Employee Stock Option (right to buy)	⁽⁶⁾	07/13/2030	Common Stock	25,000	7.2	D
Restricted Stock Units	⁽⁷⁾	⁽⁷⁾	Common Stock	14,900	⁽⁷⁾	D

Explanation of Responses:

1. This option became fully exercisable on 12/12/2019

2. This option became fully exercisable on 2/21/2020

3. This option became fully exercisable on 6/21/2019.

4. The option to purchase will vest and become exercisable over a four year period as follows: 25% on 2/9/2022 and then ratably over the remaining thirty-six months

5. This option became fully exercisable on 2/28/2021

6. The option to purchase will vest and become exercisable as follows: 25% at 7/13/2021 and the remainder ratably, on a monthly basis, over the remaining three years.

7. The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	11/03/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

			    Exhibit 24

			POWER OF ATTORNEY

	Know all by these presents, that the undersigned hereby
constitutes and appoints each of Ron Honig, Chief Legal Officer,
and Philip Hoffstein, Corporate Controller, signing singly, and
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or a director of EyePoint
Pharmaceuticals, Inc., (the "Company"), the undersigned's application
for EDGAR Access with the United States Securities and Exchange
Commission (Form ID application);

	(2)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or a director of the company,
Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder;

	(3)	do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to (A) complete
 and execute any such Forms 3, 4, or 5, (B) complete and execute any
amendment or amendments thereto, and (C) timely file such form with
the United States Securities and Exchange Commission and any stock
exchange or similar authority; and

	(4)	take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, and in the best interest of,
or legally required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

	This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3,
4, and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 3rd day of November, 2021.


				/s/ Jay S. Duker, M.D.
				____________________
				Signature

				  Jay S. Duker, M.D.
				____________________
	 			Print Name